Regentatlantic Capital LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.1% in the 4th quarter, Holdings Channel reports. The firm owned 414,394 shares of the biopharmaceutical company’s stock after selling 4,676 shares during the quarter. Pfizer comprises about 1.2% of Regentatlantic Capital LLC’s portfolio, making the stock its 14th largest holding. Regentatlantic Capital LLC’s holdings in Pfizer were worth $15,009,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer during the second quarter worth approximately $103,000. Herndon Capital Management LLC purchased a new stake in shares of Pfizer during the second quarter worth approximately $120,000. Americafirst Capital Management LLC purchased a new stake in shares of Pfizer during the third quarter worth approximately $127,000. Oak Point Wealth Management purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $165,000. Finally, Lipe & Dalton raised its stake in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 71.16% of the company’s stock.
Shares of Pfizer stock opened at $34.49 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. The firm has a market capitalization of $205,314.33, a price-to-earnings ratio of 13.02, a price-to-earnings-growth ratio of 1.73 and a beta of 0.91. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43.
Pfizer announced that its board has approved a share repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
Several research analysts have issued reports on the company. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “hold” rating in a research report on Monday, February 26th. Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday, January 8th. Finally, Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a research report on Monday, January 8th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $39.40.
In related news, EVP Rady A. Johnson sold 27,323 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $36.55, for a total transaction of $998,655.65. Following the sale, the executive vice president now owns 70,332 shares of the company’s stock, valued at $2,570,634.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now directly owns 1,000 shares in the company, valued at approximately $36,790. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 in the last three months. 0.06% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Regentatlantic Capital LLC Has $15.01 Million Stake in Pfizer Inc. (PFE)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3299226/regentatlantic-capital-llc-has-15-01-million-stake-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.